Skip to main content

mat2a inhibitor ide397

Generic: MAT2A Inhibitor IDE397

mat2a inhibitor ide397: 3 clinical trials tracked.

mat2a inhibitor ide397 evidence translation

What we can confirm

3 tracked trials

No verified listed company relationship

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage context preserved

Prepared research question

What is verified about mat2a inhibitor ide397, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence4 indications · 2 study sponsors
Clinical Trial Registry Records (3)

A Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of IDE892 as Monotherapy and Combination Therapy in Participants With MTAP-Deleted Advanced Solid Tumors

NCT07277413Registry updated 2026-09-28·Phase 1·IDYA
Recruiting

Primary endpoint: Incidence of Dose-limiting Toxicities (DLTs) of IDE892 (Parts 1 and 3)

Interventionalopen260 targetStarted 2026-03Completion 2028-0423 sites · United StatesIDEAYA Biosciences

A Phase 1/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Anvumetostat in Combination With IDE397 in Subjects With Advanced MTAP-null Solid Tumors

NCT05975073Registry updated 2026-04-22·Phase 1/Phase 2·AMGN
Completed

Primary endpoint: Part 1: Number of Participants Experiencing Dose Limiting Toxicities (DLTs)

Interventionalopen53 enrolledStarted 2023-08Completion 2026-0327 sites · Australia, Canada, Denmark, South Korea…Amgen

An Open Label, Phase 1, Treatment Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of IDE397 (MAT2A Inhibitor) In Adult Participants With Advanced Solid Tumors

NCT04794699Registry updated 2026-04-09·Phase 1·IDYA
Active, not recruiting

Primary endpoint: Dose-limiting Toxicities (DLTs) of IDE397

Interventionalopen169 enrolledStarted 2021-04Completion 2027-0237 sites · Australia, France, Germany, South Korea…IDEAYA Biosciences